Literature DB >> 12082591

A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression.

R L Roberts1, P R Joyce, R T Mulder, E J Begg, M A Kennedy.   

Abstract

The multi-drug resistance gene ABCB1 (or MDR1) encodes a P-glycoprotein (P-gp) that regulates passage of many substances across the blood-brain barrier. The antidepressant amitriptyline and its metabolites (including nortriptyline) are substrates for P-gp, and in mice lacking P-gp, penetration of amitriptyline, but not fluoxetine, into the brain is enhanced. We reasoned that polymorphic variation of P-gp may contribute to differing responses of patients to antidepressant drugs. A single nucleotide polymorphism (SNP) of ABCB1 (3435C>T) was recently correlated with expression levels and in vivo function of P-gp. We examined this SNP in patients with major depression enrolled in a randomized antidepressant treatment trial of nortriptyline and fluoxetine, and observed a significant association between nortriptyline-induced postural hypotension and 3435C>T (chi(2) = 6.78, df = 2, P = 0.034). Our results suggest that homozygosity for 3435T alleles of ABCB1 is a risk factor for occurrence of nortriptyline-induced postural hypotension (OR = 1.37, P = 0.042, 95% CI 1.01-1.86).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082591     DOI: 10.1038/sj.tpj.6500099

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  38 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 2.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 5.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 6.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 7.  The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.

Authors:  Norbert Thuerauf; Martin Friedrich Fromm
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 8.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

9.  ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.

Authors:  A Ray; L Tennakoon; J Keller; J E Sarginson; H S Ryan; G M Murphy; L C Lazzeroni; M H Trivedi; J H Kocsis; C DeBattista; A F Schatzberg
Journal:  Pharmacogenomics J       Date:  2014-12-09       Impact factor: 3.550

10.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.